[Peculiarities of Platelet Activation Changes in Patients with Chronic Schizophrenia, Depending on the Severity of Positive and Negative Symptoms during the Remission Formation].
OBJECTIVE
The aim of our study was to compare the changes in the severity of positive, negative and psychopathological PANSS symptoms which occur at an outcome of an attack in schizophrenic patients along with remission formation and the degree of platelet activation in these patients.


METHODS
Psychometric scale of the Positive and Negative Syndrome Scale (PA NSS) and the method of estimation of platelet activation based on the calculation of cells number after elution from the column with sepharose CL-2B were used.


RESULTS
The changes in the severity of the disease were estimated using the PANSS scale of chronic schizophrenic patients in remission formation. An increase in platelet activation was determined on the basis of the above described quantitative parameter. Comparison of changes in platelet activation parameter with changes in the disease severity rating detected similar statistically indistinguishable (p > 0.05) changes in the severity of positive symptoms and quantitative variable of platelet activation between the 1st and the 3rd visits in the period of remission formation. Platelet number after elution from the column during the 3rd visit was approximately two times less than during the 1st visit (p < 0.002). PANSS positive subscale shows a decrease of the severity of the syndrome by 1.6 times (p < 0.0002). In addition the difference between the platelet activation parameter and severity of the negative syndrome was fixed during the 3rd visit (p < 0.034).


CONCLUSIONS
Similar changes in the severity of positive syndrome and platelet activation parameter were presented from 1st to 3rd visit in the remission formation. A distinction between the platelet activation parameter and severity of the negative syndrome was fixed during the 3rd visit.
O S
OS
Brusov
G P
GP
Zlobina
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology; D001526:Behavioral Symptoms / Q000097:blood / Q000175:diagnosis; D015331:Cohort Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009031:Moscow; D062072:Patient Acuity; D015539:Platelet Activation / Q000187:drug effects*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011594:Psychometrics / Q000379:methods; D011599:Psychopathology; D012074:Remission Induction / Q000379:methods; D018967:Risperidone / Q000494:pharmacology*; D012559:Schizophrenia / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D013223:Statistics as Topic
D014150:Antipsychotic Agents; D018967:Risperidone